## Max Meyrath

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1717774/publications.pdf

Version: 2024-02-01

1478505 1588992 9 244 6 8 citations h-index g-index papers 9 9 9 317 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides. Nature Communications, 2020, 11, 3033.	12.8	74
2	Different contributions of chemokine Nâ€terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3. British Journal of Pharmacology, 2018, 175, 1419-1438.	5.4	52
3	Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists. Biochemical Pharmacology, 2018, 153, 299-309.	4.4	33
4	The diverse and complex roles of atypical chemokine receptors in cancer: From molecular biology to clinical relevance and therapy. Advances in Cancer Research, 2020, 145, 99-138.	5.0	23
5	The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7. Signal Transduction and Targeted Therapy, 2021, 6, 209.	17.1	17
6	Proadrenomedullin N-Terminal 20 Peptides (PAMPs) Are Agonists of the Chemokine Scavenger Receptor ACKR3/CXCR7. ACS Pharmacology and Translational Science, 2021, 4, 813-823.	4.9	15
7	Atypical opioid receptors: unconventional biology and therapeutic opportunities. , 2022, 233, 108014.		15
8	Nanoluciferase-based methods to monitor activation, modulation and trafficking of atypical chemokine receptors. Methods in Cell Biology, 2022, , 279-294.	1.1	9
9	The Extended N-Terminal Domain Confers Atypical Chemokine Receptor Properties to CXCR3-B. Frontiers in Immunology, 2022, 13, .	4.8	6